ETFs positioned on AstraZeneca PLC

Name YTD change Weight AuM
+16.37%-.--% 334,922 M€
+14.61%-.--% 2,210 M€
+8.53%-.--% 1,193 M€
+17.74%-.--% 1,646 M€
+1.47%4.85% 5 M€
+21.40%4.05% 81 M€
+1.93%3.39% 94 M€
+11.94%1.83% 331 M€
+21.76%1.5% 210 M€
+15.52%1.29% 1,882 M€
+17.85%1.15% 19 M€
+9.32%1.12% 6,576 M€
+15.47%1.06% 122 M€
+8.72%1% 13 M€
+6.46%0.62% 8 M€
+10.06%0.54% 361 M€
+6.60%0.42% 8,285 M€
+6.54%0.31% 5,369 M€
+11.23%0.3% 630 M€
+16.83%0.3% 2,914 M€
-4.77%0.3% 15 M€
+15.36%0.3% 38 M€
+17.08%0.3% 100 M€
+11.68%0.3% 16 M€
+14.99%0.29% 40 M€
+11.99%0.29% 115 M€
+17.47%0.29% 138 M€
+1.30%0.28% 13,961 M€
+15.43%0.27% 6,226 M€
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!